Malignant neoplasm of ureteric orifice
ICD-10 C67.6 is a billable code used to indicate a diagnosis of malignant neoplasm of ureteric orifice.
C67.6 refers to a malignant neoplasm located at the ureteric orifice, which is the opening where the ureters connect to the bladder. This type of cancer is part of the broader category of urinary tract malignancies, which can include cancers of the bladder, ureters, and kidneys. The ureteric orifice is particularly significant as it can be affected by transitional cell carcinoma, the most common type of bladder cancer, which may extend into the ureter. Symptoms may include hematuria (blood in urine), urinary obstruction, and changes in urinary habits. Diagnosis typically involves imaging studies, cystoscopy, and biopsy. Staging of the cancer is crucial for determining the extent of disease and guiding treatment options, which may include surgical resection, chemotherapy, or radiation therapy. Surgical management often involves procedures such as ureterectomy or radical cystectomy, depending on the tumor's size and spread. Accurate coding for C67.6 is essential for proper treatment planning and reimbursement.
Detailed operative reports, imaging studies, and pathology results are essential.
Diagnosis and management of transitional cell carcinoma, ureteral obstruction due to tumors.
Urologists must ensure accurate staging and documentation of tumor characteristics.
Comprehensive treatment plans, including chemotherapy regimens and follow-up care.
Management of advanced urinary tract malignancies and coordination of multidisciplinary care.
Oncologists should document the rationale for treatment choices and patient responses.
Performed for malignant tumors at the ureteric orifice.
Operative report detailing the procedure and findings.
Urologists must document the extent of resection and any complications.
Common symptoms include hematuria, urinary obstruction, dysuria, and changes in urinary frequency. Patients may also experience flank pain or recurrent urinary tract infections.
Diagnosis typically involves imaging studies such as CT scans or MRIs, followed by cystoscopy and biopsy to confirm the presence of malignancy.
Treatment options may include surgical resection (ureterectomy), chemotherapy, and radiation therapy, depending on the stage and extent of the cancer.
Coders need detailed operative reports, imaging results, and pathology findings to accurately code C67.6 and support the diagnosis.
